Skip to main content

Table 1 Demographic characteristics of participants

From: Initial levels of β-amyloid and tau deposition have distinct effects on longitudinal tau accumulation in Alzheimer’s disease

 

Control

A+/T−

A+/T+

Participants with concurrent Aβ PET, tau PET, and MRI at baseline (n = 487)

 A/T/N, n (%)

162 (33.3)

143 (29.4)

182 (37.4)

 Diagnosis, CU:CI

162:0

93:50

48:134

 Females, n (%)

102 (63.0)

66 (46.1)a

98 (53.8)

 Age, years, median (IQR, range)

69.1 (7.7, 55.3–85.0)

74.8 (11.2, 56.6–92.2)a

75.7 (10.9, 55.7–94.0)b

 Age < 65, n (%)

21 (13.0)

13 (9.1)

16 (8.8)

 Age < 72.7, n (%)

116 (71.6)

60 (42.0)a

67 (36.8)b

 Education, years, median (IQR, range)

17 (2, 11–20)

17 (3, 12–20)

16 (4, 12–20)b,c

 APOE-ε4, n (%)

39 (24.7)

65 (47.8)a

112 (65.9)b,c

 APOE-ε2, n (%)

19 (12.0)

5 (3.7)a

4 (2.4)b

 KL-VShet+, n (%)

43 (30.5)

35 (29.9)

24 (19.4)

 Aβ PET Centiloids, median (IQR, range)

7.1 (11.2, −17.3–22.4)

47.2 (46.2, 20.7–152.3)a

87.0 (55.8, 16.4–253.4)b,c

Participants with ≥2 Aβ PET scans (n = 199)

 A/T/N, n (%)

80 (40.2)

58 (29.1)

61 (30.7)

 Diagnosis, CU:CI

80:0

42:16

27:34

 Females, n (%)

53 (66.3)

24 (41.4)a

38 (62.3)

 Age, years, median (IQR, range)

69.2 (8.7, 58.4–83.7)

75.5 (8.9, 62.2–91.5)a

76.6 (10.7, 56.3–90.4)b

 Age < 65, n (%)

8 (10.0)

3 (5.2)

5 (8.2)

 Age < 72.7, n (%)

54 (67.5)

20 (34.5)a

21 (34.4)b

 Education, years, median (IQR, range)

17.5 (2, 11–20)

17.0 (4, 12–20)

16.0 (4, 12–20)b,c

 APOE-ε4, n (%)

24 (30.4)

31 (53.4)a

36 (59.0)b

 APOE-ε2, n (%)

9 (11.4)

1 (1.7)

3 (4.9)

 KL-VShet+, n (%)

21 (28.4)

13 (23.2)

14 (23.7)

 FU visits, median (IQR, range)

2 (0, 2–3)

2 (0, 2–3)

2 (0, 2–)

 Duration of FU, years, median (IQR, range)

2.1 (0.4, 1.3–4.2)

2.0 (0.2, 0.8–3.8)

2.1 (0.2, 1.0–3.7)

Participants with ≥2 tau PET scans (n = 192)

 A/T/N, n (%)

37 (19.3)

71 (37.0)

84 (43.8)

 Diagnosis, CU:CI

37:0

46:25

27:57

 Females, n (%)

23 (62.2)

27 (38.0)a

52 (61.9)c

 Age, years, median (IQR, range)

69.2 (9.3, 62.8–82.7)

73.9 (9.7, 58.2–92.2)a

75.8 (10.0, 55.7–89.6)b

 Age < 65, n (%)

6 (16.2)

5 (7.0)

9 (10.7)

 Age < 72.7, n (%)

26 (70.3)

30 (42.3)a

32 (38.1)b

 Education, years, median (IQR, range)

16 (3, 12–20)

17 (4, 12–20)

16 (4, 12–20)c

 APOE-ε4, n (%)

12 (32.4)

39 (56.5)a

56 (70.0)b

 APOE-ε2, n (%)

4 (10.8)

2 (2.9)

2 (2.5)

 KL-VShet+, n (%)

14 (41.2)

19 (31.1)

14 (20.9)

 FU visits, median (IQR, range)

2 (1, 2–5)

2 (1, –4)

2 (1, 2–4)

 Duration of FU, years, median (IQR, range)

2.0 (1.1, 0.9–3.7)

1.5 (1.0, 0.8–3.6)

1.5 (1.0, 0.8–4.0)

  1. A/T/N amyloid-β/tau/neurodegeneration, CU cognitive unimpaired, CI cognitive impairment, IQR interquartile range, FU follow-up
  2. aSignificant difference between the control and A+/T− at p < 0.05 with Benjamini-Hochberg corrected
  3. bSignificant difference between the control and A+/T+ at p < 0.05 with Benjamini-Hochberg corrected
  4. cSignificant difference between A+/T− and A+/T+ at p < 0.05 with Benjamini-Hochberg corrected